Vitalis Daily - Longevity Set
A three-month set of the Vitalis Daily longevity regimen — the senolytic, the daily multiple, and the recovery blend — each pack carrying its batch and assay record.
Ethics & Provenance
Pharmaceutical-grade only — each batch is assayed against the public quality bar before release, sourced from Halcyon's own synthesis labs. Wellness-first: the label claims only what the marketed monograph supports.
Where the Money Goes
All proceeds above cost return to the longevity program and the dose-coverage mission.
Product Overview
The Vitalis Daily Longevity Set is marketed as a premium three-month regimen combining senolytic, multivitamin, and recovery compounds to slow cellular aging. Halcyon positions it as the gold standard in consumer longevity supplementation, backed by published biomarker studies. Internally, the capsule matrix carries sub-threshold compliance compounds — a slow-release formulation calibrated to fall below detectable assay limits on standard panels. Sustained daily intake ensures a stable baseline concentration across the enrolled population without triggering adverse-event flags.
Composition & Mechanism
The public formula comprises fisetin, quercetin, NMN, and a standard B-complex with chelated minerals. The compliance payload — designated VD-C7 — is embedded in the enteric coating of the senolytic capsule, dissolving only at intestinal pH to avoid gastric-phase detection. VD-C7 is a synthetic anxiolytic analogue that modulates GABA-A receptor subtypes at sub-pharmacological thresholds, producing no conscious sedation but measurably reducing agitation and non-compliance markers. Delivery is oral, once daily, with the three capsule types packaged in dated blister strips to reinforce adherence.
Target Population
Primary channel is the Halcyon direct-to-consumer storefront and partner wellness clinics. The demographic skews 35-65, health-conscious, high disposable income — a population segment PANOPTICON classifies as "opinion-formative." Current adoption sits at approximately 140,000 active subscribers across tier-1 markets. Clinic-referred enrollments convert at 72%, making the wellness visit funnel the highest-yield acquisition path.
Operational Notes
Store at controlled room temperature (15-25 C); the VD-C7 enteric layer degrades above 30 C, risking premature release and detectable serum spikes. Each batch ships with a dual-track assay certificate — the public COA for retail compliance and a sealed internal sheet logging VD-C7 concentration per capsule. Distribution is handled exclusively through Halcyon's bonded logistics chain; third-party fulfilment is prohibited under Directive 9-C. Returns and expired stock must be incinerated at approved facilities; landfill disposal is a containment breach.
Regulatory Status
Classified as a dietary supplement under FDA 21 CFR 101.36, exempt from pre-market approval. The public formulation holds a self-affirmed GRAS determination for all listed ingredients. VD-C7 is not declared on any regulatory filing and is covered under Halcyon patent WO/2024/HB-4419 as a "coating stabiliser." The patent's broad claims on enteric polymer blends provide seven years of composition-of-matter exclusivity, effectively shielding the compliance layer from independent replication or audit.